How to run a before-and-after biomarker study for a supplement brand

To run a before-and-after supplement biomarker study, define one clear question and primary endpoint first, then pick validated biomarkers, collect baseline and follow-up samples the same way, include a control group where you can, get IRB review and informed consent, and test every sample at one CLIA-certified lab.
If you're still choosing markers or working out what your marketing can say, start with our post on biomarker testing for supplement brands. This one covers designing and running the study. It's general guidance, not legal, regulatory or medical advice, so review your plan with counsel, a statistician and an IRB.
Start with the question, not the panel
Every design decision flows from one sentence: what should the study show? Write it down before choosing any test.
Name one primary endpoint. For example, the change in a specific blood marker from baseline to a set follow-up date, compared with a control group.
Match the question to the claim you hope to make. A study that measures a blood level supports a claim about that level, not about how people feel or perform.
Limit secondary endpoints. Each extra marker adds cost and raises the odds of a chance finding.
The FTC's Health Products Compliance Guidance says research should begin with a clear, detailed protocol, with primary and secondary outcome measures defined in advance. It also warns that post hoc analysis that departs from the original protocol generally doesn't provide reliable evidence for a claim.
Decide what kind of study this is
The intent of the study shapes the rules that apply. FDA's guidance on whether human research studies can be conducted without an IND explains that a study evaluating a dietary supplement's effect only on the structure or function of the body doesn't need an IND. A study designed to evaluate whether a supplement can diagnose, cure, mitigate, treat or prevent a disease does.
That line matches the claims line. Under 21 CFR 101.93, structure/function statements require notification to FDA and a disclaimer, and they can't claim to treat or prevent disease. FDA's structure/function claims page is a useful plain-language overview. Settle this with counsel before writing the protocol.
Choose biomarkers you can measure consistently
A before-and-after study lives or dies on consistency. The change you're looking for can be smaller than the noise from changing how samples are collected.
Pick markers that can actually move
Choose markers that respond to the ingredient on a plausible timeline and have established reference ranges. If a marker takes months to change, a four-week study won't show much.
Lock down pre-analytic variables
Write collection rules into the protocol and keep them identical at every time point:
Timing: same time of day, and the same fasting state if the marker needs it.
Season: some markers, such as vitamin D, shift with the seasons, so a long study should plan for it.
Interfering supplements: ask about other products participants take. FDA has warned that biotin can interfere with certain lab tests.
Specimen type: don't switch from venous to fingerstick, or between kit types, midway. Use a specimen type the lab has validated for each marker.
Handling: the same kit, shipping method and stability window for every sample.
Plan baseline and follow-up timing
Take the baseline before anyone starts the product, and consider a run-in period if participants already take similar supplements. Set the follow-up date from how fast the marker can change, not from a marketing calendar. The FTC guidance also says a study should be long enough to support any claim that the effect will persist.
Set a window around each visit and record when each sample was actually collected.
Be realistic about sample size
There's no universal number. Sample size depends on how much the marker varies, how big a change matters and how many people you expect to drop out. Ask a biostatistician to run a power calculation before you budget, and plan to analyze everyone you enroll. The FTC guidance points to an intent-to-treat analysis that includes participants who dropped out or didn't follow the protocol.
An underpowered study costs less but rarely gives you anything you can use.
Control group: placebo or open-label?
An open-label, single-arm study (everyone takes the product) is cheaper, but it can't separate the product's effect from placebo effects, seasonal shifts or participants changing their habits.
The FTC guidance says human studies should have a treatment group and a control group, ideally with a placebo, plus appropriate randomization and double blinding where feasible. Results should be statistically significant and clinically meaningful, and studies with several outcomes should report all of them.
Use open-label pilots to test logistics and estimate variability, and use a randomized, placebo-controlled design for the study you plan to cite.
IRB review, consent and privacy
IRB review. The FTC guidance calls IRB submission generally accepted as a necessary step. Many IRBs use the Common Rule (45 CFR 46) as their framework. If the study falls under FDA's IND rules, FDA's informed consent and IRB regulations (21 CFR 50 and 21 CFR 56) apply. Your IRB and counsel can tell you which rules govern your study.
Informed consent. Explain what's collected, how often, the risks, how results are shared and that participants can withdraw.
Registration. The FTC guidance describes public registration, for example on ClinicalTrials.gov, as a generally accepted practice.
Privacy. Decide who can see identifiable data, how it's stored and how long you keep it. Which privacy laws apply depends on who holds the data and where participants live, so confirm with counsel.
Collection logistics for remote participants
Many brand studies enroll participants nationwide with at-home kits. That works if you plan for:
Kits that are identical for every participant and every time point.
Clear instructions, so self-collected samples arrive usable.
Prepaid return shipping and a stability window the lab has validated.
Tracking, so your team knows when a kit is late and can send a replacement before the visit window closes.
State rules on where a lab can accept specimens from. New York, for example, requires its own lab permit.
Use one CLIA-certified lab for every sample
Sending baseline and follow-up samples to different labs adds method and reference-range differences you'll have to explain. One lab and one data format keep results comparable.
CMS explains in its research testing and CLIA overview that research testing that reports patient-specific results that will be or could be used for health assessment is presumed to be subject to CLIA. If you return results to participants, confirm the lab's certification and decide how out-of-range values reach a clinician.
IHDLab is one option here: a CLIA-certified lab (CLIA 05D2040304) licensed in California, New York and Maryland that builds study kits and tests the returned specimens in its own lab. Our clinical research lab services page has details.
What results can and can't support
A well-run study gives evidence about the marker, dose, population and timeframe you tested. It doesn't automatically support:
Claims about different doses or formulations.
Broader benefit claims, such as energy or longevity, if you only measured a blood level.
Disease claims, which fall outside structure/function rules.
Claims built on a subgroup you found after the fact.
Plan the claim, the endpoint and the analysis together, and have counsel review any marketing language before it goes live.
The bottom line
A credible supplement biomarker study comes down to one clear question, consistent collection, a fair comparison, proper ethics review and one lab for every sample. If you're building the testing side of a supplement program, our supplement brand lab testing overview is a good place to start.



